STATCenter·
STAT+: AbbVie to buy Apogee Therapeutics in nearly $11B deal
AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run of pharma acquisitions.
Read at STAT →
Health · 1 sources covering this
STAT+: AbbVie to buy Apogee Therapeutics in nearly $11B deal
AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a run of pharma acquisitions.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/01cedca5b2e0e7bf788281c09e328416343f9e5b" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: AbbVie to buy Apogee Therapeutics in nearly $11B deal"></iframe>
